PL206105B1 - Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej - Google Patents

Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej

Info

Publication number
PL206105B1
PL206105B1 PL366199A PL36619901A PL206105B1 PL 206105 B1 PL206105 B1 PL 206105B1 PL 366199 A PL366199 A PL 366199A PL 36619901 A PL36619901 A PL 36619901A PL 206105 B1 PL206105 B1 PL 206105B1
Authority
PL
Poland
Prior art keywords
factor viii
leu
human
cheese
sequence
Prior art date
Application number
PL366199A
Other languages
English (en)
Polish (pl)
Other versions
PL366199A1 (en
Inventor
John S. Lollar
Original Assignee
Emory Universityemory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory Universityemory University filed Critical Emory Universityemory University
Publication of PL366199A1 publication Critical patent/PL366199A1/xx
Publication of PL206105B1 publication Critical patent/PL206105B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/10Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL366199A 2000-09-19 2001-09-19 Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej PL206105B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23404700P 2000-09-19 2000-09-19
US23646000P 2000-09-29 2000-09-29
PCT/US2001/029431 WO2002024723A1 (en) 2000-09-19 2001-09-19 Modified factor viii

Publications (2)

Publication Number Publication Date
PL366199A1 PL366199A1 (en) 2005-01-24
PL206105B1 true PL206105B1 (pl) 2010-07-30

Family

ID=26927505

Family Applications (1)

Application Number Title Priority Date Filing Date
PL366199A PL206105B1 (pl) 2000-09-19 2001-09-19 Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej

Country Status (12)

Country Link
US (1) US6770744B2 (enExample)
EP (1) EP1319016A4 (enExample)
JP (1) JP2004525608A (enExample)
KR (1) KR100638184B1 (enExample)
CN (1) CN1205221C (enExample)
AU (1) AU2001292861A1 (enExample)
CA (1) CA2422902A1 (enExample)
HU (1) HUP0301179A3 (enExample)
MX (1) MXPA03002256A (enExample)
PL (1) PL206105B1 (enExample)
RU (1) RU2003107100A (enExample)
WO (1) WO2002024723A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
MXPA04005079A (es) * 2001-11-30 2004-08-19 Univ Emory Variantes del dominio c2 del factor viii.
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US7709224B2 (en) 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7855274B2 (en) * 2003-12-03 2010-12-21 University Of Rochester Recombinant factor VIII having increased specific activity
EP1750733B1 (en) * 2004-05-03 2013-12-11 Emory University METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
SI1824988T1 (sl) 2004-11-12 2017-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
CA2703948A1 (en) * 2007-11-01 2009-05-07 University Of Rochester Recombinant factor viii having increased stability
CN104059155A (zh) * 2008-05-16 2014-09-24 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
BR112012004094A2 (pt) 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
EP2498804A4 (en) * 2009-11-13 2013-05-08 Puget Sound Blood Ct FACTOR VIII B CELL EPITOPARIANTS WITH REDUCED IMMUNOGENITY
US20110177107A1 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
US9150637B2 (en) 2010-11-05 2015-10-06 Baxalta Inc. Variant of antihemophilic factor VIII having increased specific activity
HRP20221531T1 (hr) 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Pripravci faktora viii i postupci dobivanja i korištenja istih
LT2822577T (lt) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Rekombinantiniai faktoriaus viii baltymai
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
US10093901B2 (en) 2013-05-10 2018-10-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Use of specific regulatory T-cells to induce immune tolerance
WO2014209942A1 (en) 2013-06-24 2014-12-31 Weidong Xiao Mutant factor viii compositions and methods
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
US10058624B2 (en) * 2015-04-16 2018-08-28 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US20210093735A1 (en) * 2018-04-26 2021-04-01 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of hemophilia
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
CN117157316A (zh) 2021-03-30 2023-12-01 艾诺健基因治疗股份有限公司 修饰的血浆凝血因子viii及其使用方法
CN113970279B (zh) * 2021-10-26 2023-07-07 珠海城市职业技术学院 数字式螺旋测微仪
CN114196677A (zh) * 2021-12-30 2022-03-18 广西医科大学第一附属医院 一种高活性的凝血因子Ⅷ或Ⅷa多肽变体Gly710Ala

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
CA2225189C (en) * 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
AU6770200A (en) * 1999-08-13 2001-03-13 Fred Hutchinson Cancer Research Center Crystal of a truncated protein construct containing a coagulation factor viii c2domain in the presence or absence of a bound ligand and methods of use thereof
EP1460131A3 (en) * 2000-03-22 2005-06-01 Octagene GmbH Production of recombinant blood clotting factors in human cell lines

Also Published As

Publication number Publication date
JP2004525608A (ja) 2004-08-26
CA2422902A1 (en) 2002-03-28
RU2003107100A (ru) 2004-08-27
AU2001292861A1 (en) 2002-04-02
PL366199A1 (en) 2005-01-24
EP1319016A4 (en) 2006-05-10
US20020182670A1 (en) 2002-12-05
HUP0301179A2 (hu) 2003-10-28
KR100638184B1 (ko) 2006-10-26
KR20030033074A (ko) 2003-04-26
CN1205221C (zh) 2005-06-08
US6770744B2 (en) 2004-08-03
HUP0301179A3 (en) 2006-11-28
MXPA03002256A (es) 2003-09-10
WO2002024723A9 (en) 2003-04-03
WO2002024723A1 (en) 2002-03-28
EP1319016A1 (en) 2003-06-18
CN1474830A (zh) 2004-02-11

Similar Documents

Publication Publication Date Title
US6770744B2 (en) Modified factor VIII
RU2285724C2 (ru) Рекомбинантная молекула днк, кодирующая модифицированный свиной фактор viii (pol 1212), экспрессирующие векторы, модифицированный свиной фактор viii, терапевтическая композиция, способы получения белка модифицированного свиного фактора viii (варианты) и линии клеток (варианты)
CA2374675C (en) Modified factor viii
EP0910628B1 (en) Inactivation resistant factor viii
US20050123997A1 (en) Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
EP1561757A1 (en) Modified factor VIII
US20120190623A1 (en) Inactivation Resistant Factor VIII
IL138281A (en) Modified factor viii
CA2461443C (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
WO2003047507A2 (en) Factor viii c2 domain variants
HK1078596A (en) Modified factor viii

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20100919